Gazyvaro

(obinutuzumab)

Uses, side effects, dosage information & price range

Roche Registration GmbH

About this medicine

Chronic lymphocytic leukaemia (CLL) Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.  Follicular Lymphoma (FL)  Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.   Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.  Lupus nephritis (LN) Gazyvaro in combination with mycophenolate mofetil (MMF) is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN). 

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

PoherdyComposition: pertuzumabOrganon N.V.

Price on RequestView Details →

MekinistComposition: trametinibNovartis Europharm Limited

Price on RequestView Details →

VijoiceComposition: alpelisibNovartis Europharm Limited

Price on RequestView Details →

KisqaliComposition: ribociclibNovartis Europharm Limited

Price on RequestView Details →

TecartusComposition: brexucabtagene autoleucelKite Pharma EU B.V.

Price on RequestView Details →

Key Information

Salt / Composition

obinutuzumab